Best of ASCO 2024, Milwaukee

Milwaukee, WI US
June 29, 2024 to June 30, 2024

This CME-accredited oncology conference, Best of ASCO 2024, Milwaukee, is designed to improve the care of cancer patients by educating clinicians involved in cancer care.

Expert faculty will provide a comprehensive overview of practice-changing abstracts presented at the 2024 ASCO® Annual Meeting (ASCO2024) in June 2024. The program includes in-depth discussion and analysis of the latest scientific findings and practice-changing advances in the field. Expert faculty will place abstract findings from ASCO2024 into clinical contexts and discuss how the results may change the current standard of care. This conference is designed to provide physicians, physician assistants, nurse practitioners, pharmacists, nurses, and other healthcare professionals with the latest updates in the field. It will highlight a multidisciplinary approach and the integration of new advances in patient-centered care.

Target Audience

  • Medical oncologists
  • Radiation oncologists
  • Surgical oncologists
  • Oncology residents/fellows
  • Oncology NPs/PAs
  • Oncology pharmacists
  • Oncology nurses

ORGANIZING COMMITTEE: 

Course Director

Binay Shah, MD, MHA - Binaytara Foundation

Conference Chairs

Deepak Kilari, MD - Froedtert Hospital and Medical College of Wisconsin

Jonathan Thompson, MD, MS - Froedtert Hospital and Medical College of Wisconsin

VENUE INFORMATION

Booking link:  https://www.hyatt.com/en-US/group-booking/MKERM/G-BFRB. Book your rooms by or before May 31, 2024.

Learning Objectives

At the conclusion of the activity, participants will be able to:

  1. Discuss new and updated treatment options for patients with hematologic malignancies and solid tumors
  2. Identify side effects, indications, and contra-indications of therapies used to diagnose and treat cancers
  3. Explain how to effectively manage side-effects associated with cancer treatment
  4. Review abstracts presented at ASCO® 2024 and discuss their application in clinical settings

GLOBAL ONCOLOGY PROJECT

Click this link to learn more about our ongoing project building a 200-bed cancer hospital in Nepal: https://binayfoundation.org/cancer-hospital/

Course summary
Available credit: 
  • 10.00 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 10.00 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 10.00 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 10.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 10.00 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 10.00 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 10.00 Contact Hours.
Course opens: 
12/20/2023
Course expires: 
08/31/2024
Event starts: 
06/29/2024 - 7:00am PDT
Event ends: 
06/30/2024 - 4:00pm PDT
Cost:
$350.00

DAY 1 - JUNE 29th, 2024


All times below are listed in Central Time (CT).

07:00 AM – 08:00 AM  Registration, Breakfast, & Exhibits


08:00 AM – 08:05 AM  Welcome

08:05 AM – 08:20 AM  Binaytara Foundation's Efforts in Improving Cancer Care Disparities - Binay Shah, MD, MHA


08:20 AM – 09:50 AM  Session 1 - Hematologic Malignancies

Session Chair: Guru Subramanian Guru Murthy, MD, MS

08:20 AM – 08:50 AM  MDS/Leukemias - Ehab Atallah, MD

08:50 AM – 09:20 AM  Multiple Myeloma - Ravi Narra, MD, MS

09:20 AM – 09:50 AM  Lymphoma & CLL - Nirav Shah, MD


09:50 AM – 10:20 AM  Break & Exhibits


10:20 AM – 11:50 AM  Session 2 - Thoracic Oncology

Session Chair: Jonathan Thompson, MD, MS

10:20 AM –10:50 AM  Early-Stage NSCLC - Jonathan Thompson, MD, MS

10:50 AM – 11:20 AM  Metastatic NSCLC - Smitha Menon, MD

11:20 AM – 11:50 AM  Small Cell Lung Cancer - Hui-Zi Chen, MD, PhD


11:50 AM – 12:50 PM  Lunch & Exhibits


12:50 PM – 02:30 PM  Session 3 - Case-Based Presentations 1

Session Chair: David Knight, MD

12:50 PM – 01:10 PM  Case 1: Sarcoma - John Charlson, MD

01:10 PM – 01:30 PM  Case 2: Brain Tumor Updates - Jennifer Connelly, MD

01:30 PM – 01:50 PM  Case 3: Cutaneous Malignancies - Ryan Nguyen, DO

01:50 PM – 02:10 PM  Case 4: Palliative Care/Supportive Therapy - Jordan Bauman, MD

02:10 PM – 02:30 PM  Panel Discussion


02:30 PM – 03:00 PM  Break & Exhibits


03:00 PM – 04:30 PM  Session 4 - Genitourinary Cancer

Session Chair: Deepak Kilari, MD

03:00 PM – 03:20 PM  Prostate Cancer - Christos Kyriakopoulos, MD

03:20 PM – 03:40 PM  Bladder Cancer - Yousef Zakharia, MD

03:40 PM – 04:00 PM  Kidney Cancer - Benjamin Maughan, MD, PharmD

04:00 PM – 04:30 PM  Case-Based Discussion


DAY 2 - JUNE 30th, 2024
 

07:00 AM – 08:00 AM  Registration, Breakfast, & Exhibits


08:00 AM – 09:00 AM  Session 5 - Case-Based Presentations 2

Session Chair: Adam Siegel, MD

08:00 AM – 08:15 AM  Case 1: Gynecologic Cancer - Denise Uyar, MD

08:15 AM – 08:30 AM  Case 2: Head/Neck Cancer - Stuart Wong, MD

08:30 AM – 08:45 AM  Case 3: GI Cancer - Harsha Poola, MD

08:45 AM – 09:00 AM  Case 4: Breast Cancer - Bradley Heraly, MD


09:00 AM – 10:30 AM  Session 6 - GI Cancer

Session Chair: Ben George, MD

09:00 AM – 09:30 AM  Colorectal Cancer - James P Thomas, MD, PhD

09:30 AM – 10:00 AM  Pancreatic Malignancies - Mandana Kamgar, MD, MPH

10:00 AM – 10:30 AM  Upper GI Cancer - Ben George, MD


10:30 AM – 10:45 AM  Break & Exhibits


10:45 AM – 12:15 PM  Session 7 - Breast Cancer

Session Chair: Sailaja Kamaraju, MD

10:45 AM – 11:15 AM  Hormone Receptor Positive Breast Cancer - Lubna Chaudhary, MD

11:15 AM – 11:45 AM  HER2 Positive Breast Cancer - William J Gradishar, MD

11:45 AM – 12:15 PM  Triple Negative Breast Cancer - Kari B. Wisinski, MD


12:15 PM   Adjourn

Hyatt Regency Milwaukee
333 W Kilbourn Ave
Milwaukee, WI 53203
United States

Booking link:  https://www.hyatt.com/en-US/group-booking/MKERM/G-BFRB. Book your rooms by or before May 31, 2024.

IDENTIFICATION AND MITIGATION OF POTENTIAL CONFLICT OF INTERESTS:

All conflict of interest has been identified and mitigated for individuals in control of contents.

PLANNING COMMITTEE DISCLOSURE STATEMENT:

None of the members of the planning committee, nor any member of their immediate families, have a relevant financial interest in or affiliation with any commercial supporter of this educational activity and/or with the manufacturer(s) of commercial products and/or providers of any commercial services discussed in this educational activity.

Conference Chair(s)

Deepak Kilari

has a financial relationship (Professional Services) with Eisai;.
has a financial relationship (Professional Services) with MJH life science;.
has a financial relationship (Professional Services) with Astellas ;.
has a financial relationship (Professional Services) with Aveo Oncology ;.
has a financial relationship (Grant Or Contract) with Genentech;.
has a financial relationship (Professional Services) with Jannsen ;.
has a financial relationship (Grant Or Contract) with Exelixis ;.

Jonathan Thompson, MD, MS

has a financial relationship (Other) with AstraZeneca;.
has a financial relationship (Other) with Regeneron;.
has a financial relationship (Other) with GE Healthcare;.
Session Chair(s)

Guru Subramanian Guru Murthy, MD, MS

has a financial relationship (Other) with Pfizer;.
has a financial relationship (Other) with Autolus;.
has a financial relationship (Other) with Gilead;.
has a financial relationship (Other) with Kite;.
has a financial relationship (Other) with Amgen;.
has a financial relationship (Other) with BMS;.
has a financial relationship (Other) with Rigel;.
has a financial relationship (Other) with BeiGene;.
has a financial relationship (Other) with Amgen;.

Sailaja Kamaraju

has no relevant financial relationships to disclose at this time.
Speaker/Topic Presenter(s)

Ehab Atallah, MD

has a financial relationship (Independent contractor) with Abbvie;.
has a financial relationship (Independent contractor) with BMS;.
has a financial relationship (Grant Or Contract) with Novartis;.
has a financial relationship (Independent contractor) with Pfizer;.

Lubna Chaudhary

has a financial relationship (Other) with Regeneron Pharmaceuticals;.
has a financial relationship (Professional Services) with Astrazeneca;.
has a financial relationship (Professional Services) with Novartis;.

William Gradishar

has a financial relationship (Professional Services) with Lilly;.
has a financial relationship (Professional Services) with AstraZeneca;.

Mandana Kamgar, MD, MPH

has a financial relationship (Grant Or Contract) with Cornerstone;.
has a financial relationship (Grant Or Contract) with ONECELL;.

Christos Kyriakopoulos, MD, MSCI

has a financial relationship (Grant Or Contract) with ESSA Pharma;.
has a financial relationship (Grant Or Contract) with Merck;.
has a financial relationship (Stock) with Biogen;.
has a financial relationship (Grant Or Contract) with BMS;.
has a financial relationship (Grant Or Contract) with Merck KGaA;.
has a financial relationship (Professional Services) with Pfizer;.
has a financial relationship (Grant Or Contract) with AstraZeneca;.
has a financial relationship (Grant Or Contract) with Madison Vaccines, Inc;.
has a financial relationship (Grant Or Contract) with Sanofi-Aventis;.
has a financial relationship (Grant Or Contract) with Gilead Sciences;.
has a financial relationship (Grant Or Contract) with Pionyr Immunotherapeutics;.
has a financial relationship (Stock) with Epic Systems;.

Benjamin Maughan, M.D., PharmD

has a financial relationship (Independent contractor) with Peloton Therapeutis;.
has a financial relationship (Independent contractor) with Janssen;.
has a financial relationship (Independent contractor) with Tempus;.
has a financial relationship (Independent contractor) with Bayer Oncology;.
has a financial relationship (Independent contractor) with AVEO Oncology;.
has a financial relationship (Independent contractor) with Clovis;.
has a financial relationship (Independent contractor) with Exelixis;.
has a financial relationship (Independent contractor) with Sanofi;.
has a financial relationship (Independent contractor) with Pfizer;.
has a financial relationship (Independent contractor) with Bristol-Myers Squibb;.
has a financial relationship (Independent contractor) with Lilly;.
has a financial relationship (Independent contractor) with Abbvie;.
has a financial relationship (Independent contractor) with Astellas;.
has a financial relationship (Independent contractor) with Merck;.

Smitha Menon

has no relevant financial relationships to disclose at this time.

Ravi Kishore Narra, MD.,MS

has no relevant financial relationships to disclose at this time.

Nirav Shah, MD

has a financial relationship (Independent contractor) with Janssen;.
has a financial relationship (Stock) with Tundra Therapeutics;.
has a financial relationship (Independent contractor) with Loxo-Lilly;.
has a financial relationship (Independent contractor) with Incyte;.
has a financial relationship (Independent contractor) with TG Therapeutics;.
has a financial relationship (Independent contractor) with Seattle Genetics;.
has a financial relationship (Independent contractor) with Kite;.
has a financial relationship (Independent contractor) with BMS-Juno;.
has a financial relationship (Independent contractor) with Epizyme;.
has a financial relationship (Independent contractor) with Miltenyi Biotec;.

James Thomas, MD, PhD.

has no relevant financial relationships to disclose at this time.

Jonathan Thompson, MD, MS

has a financial relationship (Other) with GE Healthcare;.
has a financial relationship (Other) with AstraZeneca;.
has a financial relationship (Other) with Regeneron;.

Kari Wisinski, Professor, Chief of Hematology, Medical Oncology and Palliative Care

has a financial relationship (Other) with Relay;.
has a financial relationship (Other) with Genentech/Roche;.
has a financial relationship (Other) with Pfizer;.
has a financial relationship (Independent contractor) with Gilead;.
has a financial relationship (Other) with AstraZeneca;.
has a financial relationship (Independent contractor) with Pfizer;.
has a financial relationship (Independent contractor) with Stemline;.
has a financial relationship (Independent contractor) with AstraZeneca;.
has a financial relationship (Other) with Context Therapeutics;.
has a financial relationship (Grant Or Contract) with Pfizer;.
has a financial relationship (Other) with Novartis;.
has a financial relationship (Independent contractor) with LoxoLilly;.
has a financial relationship (Other) with Jazz pharmaceuticals;.
has a financial relationship (Other) with Seagen;.
has a financial relationship (Grant Or Contract) with Novartis;.
has a financial relationship (Independent contractor) with Seagen;.

Yousef Zakharia, MD

has a financial relationship (Professional Services) with Seagen ;.
has a financial relationship (Professional Services) with Janssen;.
has a financial relationship (Professional Services) with Eisai ;.
has a financial relationship (Professional Services) with Exelixis;.
has a financial relationship (Professional Services) with Gilead ;.
Case Presenter(s)

John Charlson, MD

has a financial relationship (Other) with Springworks;.
has a financial relationship (Other) with Adaptimmune;.
has a financial relationship (Other) with Deciphera;.
has a financial relationship (Other) with Boehringer Ingelheim;.

Jennifer Connelly

has a financial relationship (Travel) with Novocure;.
has a financial relationship (Grant Or Contract) with IQ-AI;.

Bradley Heraly

has a financial relationship (Professional Services) with Seagen;.

Ryan Nguyen, D.O.

has a financial relationship (Grant Or Contract) with Exelixis ;.
has a financial relationship (Financial Support) with Merck;.
has a financial relationship (Financial Support) with Novartis;.

Harsha Poola

has no relevant financial relationships to disclose at this time.

Denise Uyar, MD

has no relevant financial relationships to disclose at this time.

Available Credit

  • 10.00 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 10.00 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 10.00 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 10.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 10.00 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 10.00 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 10.00 Contact Hours.

If you are interested in exhibiting at this meeting, please visit our exhibit page here - https://education.binayfoundation.org/exhibit-information

 

Price

Cost:
$350.00
Please login or register to take this course.

POLICY ON INDUSTRY EMPLOYEE'S PARTICIPATION IN MARKETING/EDUCATION ACTIVITY AT THE CONFERENCE: 

All marketing and product promotion activities must occur in the designated exhibit hall or product theater space separate from the area where this accredited continuing education takes place. 

The exhibit and product promotion space is reserved only for companies that have purchased marketing and product promotion slots at the conference.  The individual registration fee doesn't include marketing or product theater privileges. Please refer to the sponsorship handbook for the types of marketing activities included in your display/sponsorship fees. 

If your company has NOT purchased a marketing opportunity such as an exhibit table, product theater slot or another type of marketing opportunity, you may not participate in any marketing activity or attempt to educate healthcare providers about your product or service. Industry attendees of companies without marketing opportunities must refrain from interacting with healthcare providers at this meeting in any form, including introducing themselves as an employee of the company, discussing the care of patients, handing out flyers and brochures, inviting participants to the company's other programs, etc.

Violating this policy will result in a fine equivalent to a general display fee for that conference. 

If your company has purchased an exhibit or sponsorship, please register at the link below to receive the discounted registration fees:

Link to register as an additional rep of a sponsoring company: https://education.binayfoundation.org/industry_registraiton_nocme 

NOTICE TO HCPS EMPLOYED BY THE INDUSTRY:

If you are employed by industry, including pharmaceuticals and biotech companies, you must pay the INDUSTRY REGISTRATION FEE to participate in any meeting organized by the Binaytara Foundation. If you misrepresented yourself as a healthcare provider not employed by the industry and failed to pay the Industry registration fee, the following fees apply:

  • If your company has purchased a display table at the event, you will be billed the full INDUSTRY REGISTRATION FEE plus a fine equivalent to the full industry registration fee for that event = 2 X the industry registration fee.
  • If your company has NOT purchased a display table at the event AND you attended the meeting without paying a full industry registration fee, you will be billed a full GENERAL DISPLAY FEE for that event. 
  • If your company has NOT purchased a display table at the event AND you attended the meeting paying a full industry registration fee, BUT YOU PARTICIPATED IN MARKETING AND PROMOTIONAL ACTIVITIES, you will be billed a full GENERAL DISPLAY FEE for that event. 

Any outstanding display fee, registration fee, and fines must be paid before the industry employee or the company will be able to attend/display at our conferences again.

CANCELLATION POLICY

You may cancel your enrollment at any time. Cancellation fees apply as below:

  • 50% of the paid registration fee will be refunded if registration is canceled six weeks before the conference.
  • No refunds will be issued if registration is canceled after that date.  

No credits will be offered if you do not complete all required steps of this activity, including registration and participation in the live meeting.